-+ 0.00%
-+ 0.00%
-+ 0.00%

Medtide unit Chinese Peptide completes US FDA pre-license inspection for Hepcludex API facility

PUBT·07/31/2026 08:35:19
Listen to the news
Medtide unit Chinese Peptide completes US FDA pre-license inspection for Hepcludex API facility
  • Chinese Peptide, a wholly owned Medtide subsidiary, cleared a US FDA pre-license inspection for Hepcludex API at its Hangzhou cGMP site.
  • The onsite audit ran Jan. 26 to Feb. 3, 2026, covering commercial manufacturing for bulevirtide-gmod 8.5 mg injection API.
  • Hepcludex won US FDA accelerated approval on May 22, 2026, positioning Chinese Peptide to support US commercial supply.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtide Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260731-12263601), on July 31, 2026, and is solely responsible for the information contained therein.